edoc

Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study

Naegele, Matthias and Kirsch, Monika and Ihorst, Gabriele and Fierz, Katharina and Engelhardt, Monika and De Geest, Sabina. (2018) Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 26 (3). pp. 833-841.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/68495/

Downloads: Statistics Overview

Abstract

High-dose melphalan and autologous stem cell transplantation (ASCT) are associated with high symptom burden. This study aimed to explore multiple myeloma (MM) patients' experience of symptom frequency, intensity, and distress during therapy.; This descriptive longitudinal study enrolled 29 MM patients who completed the 43-item PROVIVO questionnaire, measuring symptom experience across the dimensions of frequency, intensity, and distress at four assessment points: hospital admission (T0), leucocyte nadir (T1), discharge (T2), and 30 days post discharge (T3). Symptom assessment covered five categories: (1) physical, (2) emotional, (3) cognitive, (4) male/female urogenital symptoms, and (5) follow-up care planning (e.g., financial problems). Results were displayed as heat maps and bubble graphs for each patient, differences between T0 and T4 individually assessed, and intensity (IMS) and mean distress scores (DMS) calculated on a scale from 0 to 4.; The most frequent, intense, and distressing physical symptoms were fatigue, diarrhea, and decreased appetite. As expected, peak symptom intensity (decreased appetite 2.79) and distress (diarrhea 2.11) were reported during high-dose melphalan and the leucocyte nadir (T1). Thereafter, most symptoms' intensity and distress improved. Items on urogenital symptoms remained predominantly unanswered or patients were sexually inactive.; PROVIVO enabled exploration of various dimensions of MM patients' symptom experiences, which differed substantially before and after ASCT. Our results suggest that high-dose melphalan, ASCT, and other intensive novel agent therapies warrant targeted symptom management programs that include focused patient support.
Faculties and Departments:03 Faculty of Medicine > Departement Public Health > Institut für Pflegewissenschaft
03 Faculty of Medicine > Departement Public Health > Institut für Pflegewissenschaft > Pflegewissenschaft (De Geest)
UniBasel Contributors:De Geest, Sabina M. and Kirsch, Monika and Fierz, Katharina
Item Type:Article, refereed
Article Subtype:Research Article
ISSN:1433-7339
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:15 Apr 2020 15:52
Deposited On:15 Apr 2020 15:52

Repository Staff Only: item control page